ATE534730T1 - DIAGNOSIS AND TREATMENT OF MULTIPLE SULFATASE DISEASES AND OTHERS USING AN ENZYME THAT PRODUCES FORMYLGLYCIN - Google Patents
DIAGNOSIS AND TREATMENT OF MULTIPLE SULFATASE DISEASES AND OTHERS USING AN ENZYME THAT PRODUCES FORMYLGLYCINInfo
- Publication number
- ATE534730T1 ATE534730T1 AT04709824T AT04709824T ATE534730T1 AT E534730 T1 ATE534730 T1 AT E534730T1 AT 04709824 T AT04709824 T AT 04709824T AT 04709824 T AT04709824 T AT 04709824T AT E534730 T1 ATE534730 T1 AT E534730T1
- Authority
- AT
- Austria
- Prior art keywords
- diagnosis
- treatment
- formylglycin
- enzyme
- diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0051—Oxidoreductases (1.) acting on a sulfur group of donors (1.8)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y108/00—Oxidoreductases acting on sulfur groups as donors (1.8)
- C12Y108/99—Oxidoreductases acting on sulfur groups as donors (1.8) with other acceptors (1.8.99)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/06—Sulfuric ester hydrolases (3.1.6)
- C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
This invention relates to methods and compositions for the diagnosis and treatment of Multiple Sulfatase Deficiency (MSD) as well as other sulfatase deficiencies. More specifically, the invention relates to isolated molecules that modulate post-translational modifications on sulfatases. Such modifications are essential for proper sulfatase function.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US44774703P | 2003-02-11 | 2003-02-11 | |
PCT/US2004/003632 WO2004072275A2 (en) | 2003-02-11 | 2004-02-10 | Diagnosis and treatment of multiple sulfatase deficiency and other using a formylglycine generating enzyme (fge) |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE534730T1 true ATE534730T1 (en) | 2011-12-15 |
Family
ID=32869644
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT04709824T ATE534730T1 (en) | 2003-02-11 | 2004-02-10 | DIAGNOSIS AND TREATMENT OF MULTIPLE SULFATASE DISEASES AND OTHERS USING AN ENZYME THAT PRODUCES FORMYLGLYCIN |
Country Status (18)
Country | Link |
---|---|
US (4) | US8227212B2 (en) |
EP (3) | EP2325302B1 (en) |
JP (3) | JP5241101B2 (en) |
CN (4) | CN1759176B (en) |
AT (1) | ATE534730T1 (en) |
AU (2) | AU2004210936C1 (en) |
CA (1) | CA2515708A1 (en) |
CY (1) | CY1117346T1 (en) |
DK (2) | DK1592786T3 (en) |
ES (3) | ES2555056T3 (en) |
HK (3) | HK1090088A1 (en) |
HU (1) | HUE027210T2 (en) |
MX (2) | MX345056B (en) |
NZ (4) | NZ603330A (en) |
PT (1) | PT1592786E (en) |
SI (1) | SI2325302T1 (en) |
WO (1) | WO2004072275A2 (en) |
ZA (1) | ZA200506378B (en) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX345056B (en) * | 2003-02-11 | 2017-01-16 | Transkaryotic Therapies Inc | Diagnosis and treatment of multiple sulfatase deficiency and other using a formylglycine generating enzyme (fge). |
US8741260B2 (en) * | 2005-10-07 | 2014-06-03 | Armagen Technologies, Inc. | Fusion proteins for delivery of GDNF to the CNS |
US8497246B2 (en) * | 2006-08-18 | 2013-07-30 | Armagen Technologies, Inc. | Methods for diagnosing and treating CNS disorders by trans-blood-brain barrier delivery of protein compositions |
US7985783B2 (en) | 2006-09-21 | 2011-07-26 | The Regents Of The University Of California | Aldehyde tags, uses thereof in site-specific protein modification |
EP2182980A4 (en) | 2007-07-27 | 2012-04-18 | Armagen Technologies Inc | Methods and compositions for increasing alpha-iduronidase activity in the cns |
BRPI0817233A2 (en) | 2007-09-28 | 2012-11-06 | Intrexon Corp | therapeutic constructs of trca gene and bireactors for the expression of biotherapeutic molecules, and uses thereof |
US7722865B2 (en) | 2008-01-18 | 2010-05-25 | Biomarin Pharmaceutical Inc. | Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof |
WO2009091994A2 (en) * | 2008-01-18 | 2009-07-23 | Biomarin Pharmaceutical Inc. | Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof |
US8729232B2 (en) * | 2008-03-27 | 2014-05-20 | The Regents Of The University Of California | Aldehyde tags, uses thereof in site-specific protein modification |
US9238878B2 (en) | 2009-02-17 | 2016-01-19 | Redwood Bioscience, Inc. | Aldehyde-tagged protein-based drug carriers and methods of use |
EP2408474B1 (en) | 2009-03-18 | 2019-06-26 | Armagen, Inc. | Compositions and methods for blood-brain barrier delivery of igg-decoy receptor fusion proteins |
EP2483406A2 (en) | 2009-09-30 | 2012-08-08 | President and Fellows of Harvard College | Methods for modulation of autophagy through the modulation of autophagy-inhibiting gene products |
HUE044865T2 (en) | 2009-10-09 | 2019-11-28 | Armagen Inc | Methods and compositions for increasing iduronate 2-sulfatase activity in the cns |
US8351868B2 (en) * | 2009-11-20 | 2013-01-08 | Motorola Solutions, Inc. | Radio status indicator |
EP2394667A1 (en) | 2010-06-10 | 2011-12-14 | Laboratorios Del Dr. Esteve, S.A. | Vectors and sequences for the treatment of diseases |
AR082319A1 (en) | 2010-07-22 | 2012-11-28 | Biomarin Pharm Inc | PRODUCTION OF A HIGHLY ACTIVE PHOSPHORILED HUMAN N-ACETILGALACTOSAMINE-6-SULPHATASE AND ITS USES |
US9540438B2 (en) | 2011-01-14 | 2017-01-10 | Redwood Bioscience, Inc. | Aldehyde-tagged immunoglobulin polypeptides and methods of use thereof |
WO2012101671A1 (en) | 2011-01-25 | 2012-08-02 | Jcr Pharmaceuticals Co., Ltd. | Method for production of human recombinant iduronate 2-sulfatase |
US20160145589A1 (en) | 2011-06-24 | 2016-05-26 | Green Cross Corporation | Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof |
KR101158673B1 (en) | 2011-06-24 | 2012-07-03 | 주식회사 지씨바이오 | Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof |
EP2785378B1 (en) | 2011-12-02 | 2020-05-13 | Armagen, Inc. | Methods and compositions for increasing arylsulfatase a activity in the cns |
EP2799862B1 (en) | 2011-12-20 | 2017-03-08 | JCR Pharmaceuticals CO., LTD. | Method for analyzing formyl glycine residue |
WO2013148323A1 (en) * | 2012-03-30 | 2013-10-03 | Shire Human Genetic Therapies | Methods of analyzing and preparing protein compositions |
CA2868466A1 (en) | 2012-03-30 | 2013-10-03 | Shire Human Genetic Therapies, Inc. | Subcutaneous administration of iduronate-2-sulfatase |
US9150841B2 (en) | 2012-06-29 | 2015-10-06 | Shire Human Genetic Therapies, Inc. | Cells for producing recombinant iduronate-2-sulfatase |
US20140004097A1 (en) * | 2012-06-29 | 2014-01-02 | Shire Human Genetic Therapies, Inc. | Method of producing recombinant iduronate-2-sulfatase |
KR101380740B1 (en) * | 2012-06-29 | 2014-04-11 | 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 | Purification of iduronate-2-sulfatase |
WO2014016873A1 (en) | 2012-07-26 | 2014-01-30 | Jcr Pharmaceuticals Co., Ltd. | Method for production of recombinant human alpha-galactosidase a |
JP6692293B2 (en) * | 2013-07-22 | 2020-05-13 | アーマジェン・インコーポレイテッドArmagen, Inc. | Methods and compositions for increasing enzyme activity in the CNS |
EP3912635A1 (en) * | 2014-07-11 | 2021-11-24 | Biostrategies LC | Materials and methods for treating disorders associated with sulfatase enzymes |
MA41198A (en) | 2014-12-18 | 2017-10-24 | Shire Human Genetic Therapies | ENZYMATIC ACTIVITY TESTS FOR I2S |
US10538589B2 (en) | 2015-01-14 | 2020-01-21 | Armagen Inc. | Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU |
WO2016116966A1 (en) | 2015-01-22 | 2016-07-28 | Jcr Pharmaceuticals Co., Ltd. | Method for purification of recombinant human alpha-galactosidase a from material containing contaminant host cell proteins |
JPWO2016121715A1 (en) * | 2015-01-26 | 2017-11-02 | 国立大学法人名古屋大学 | Method for providing information for evaluating prognosis of lung cancer patient, prognosis prediction method for lung cancer patient, internal standard, antibody, prognosis prediction device for lung cancer patient, program for prognosis prediction device, and recording medium |
KR102638596B1 (en) | 2015-02-05 | 2024-02-21 | 알.피.쉐러 테크놀러지즈 엘엘씨 | Activated formylglycine-producing enzyme and methods for its production and use |
US11208632B2 (en) | 2016-04-26 | 2021-12-28 | R.P. Scherer Technologies, Llc | Antibody conjugates and methods of making and using the same |
WO2018060097A1 (en) * | 2016-09-30 | 2018-04-05 | Laboratorios Del Dr. Esteve, S. A. | Adenoassociated virus vectors for the treatment of mucopolysaccharidoses |
MX2019007824A (en) | 2016-12-28 | 2019-09-09 | Japan Chem Res | Lyophilized preparation. |
KR20190112003A (en) | 2017-01-18 | 2019-10-02 | 비스테라, 인크. | Antibody Molecular-Drug Conjugates and Uses thereof |
PE20210347A1 (en) | 2017-10-02 | 2021-02-25 | Denali Therapeutics Inc | FUSION PROTEINS INCLUDING ENZYMES FROM ENZYME REPLACEMENT THERAPY |
CN109628426B (en) * | 2019-01-02 | 2023-05-09 | 山东大学 | Delta 4, 5-hexuronic acid-2-O-sulfatase, encoding gene and application thereof, and identification method of homologous enzyme |
CN109781997A (en) * | 2019-01-22 | 2019-05-21 | 中国人民解放军总医院 | For diagnosing biomarker and its application of hunter syndrome |
CN116710146A (en) | 2020-04-03 | 2023-09-05 | 威特拉公司 | Antibody molecule-drug conjugates and uses thereof |
US20210361778A1 (en) * | 2020-04-06 | 2021-11-25 | Homology Medicines, Inc. | Adeno-associated virus compositions for ids gene transfer and methods of use thereof |
CN112630430B (en) * | 2020-11-16 | 2021-08-27 | 北京美联泰科生物技术有限公司 | Kit for quantitatively detecting UCHL-1 and application thereof |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US307A (en) | 1837-07-29 | Rqss winans | ||
US3307A (en) | 1843-10-18 | Laben eddy | ||
US3854480A (en) | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
US4675189A (en) | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
US4452775A (en) | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
US4748024A (en) | 1987-04-06 | 1988-05-31 | Endocon, Inc. | Flash flow fused medicinal implants |
US5674722A (en) | 1987-12-11 | 1997-10-07 | Somatix Therapy Corporation | Genetic modification of endothelial cells |
ATE189526T1 (en) | 1988-10-28 | 2000-02-15 | Genentech Inc | METHOD FOR DETECTING ACTIVE DOMAIN AND AMINO ACID RESIDUE IN POLYPEPTIDES AND HORMONE VARIANTS |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
US5391723A (en) | 1989-05-31 | 1995-02-21 | Neorx Corporation | Oligonucleotide conjugates |
US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
GB9019812D0 (en) | 1990-09-11 | 1990-10-24 | Scotgen Ltd | Novel antibodies for treatment and prevention of infection in animals and man |
US5641670A (en) | 1991-11-05 | 1997-06-24 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
US5968502A (en) | 1991-11-05 | 1999-10-19 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
US6270989B1 (en) | 1991-11-05 | 2001-08-07 | Transkaryotic Therapies, Inc. | Protein production and delivery |
US5932211A (en) * | 1991-11-12 | 1999-08-03 | Women's And Children's Hospital | Glycosylation variants of iduronate 2-sulfatase |
US5407686A (en) | 1991-11-27 | 1995-04-18 | Sidmak Laboratories, Inc. | Sustained release composition for oral administration of active ingredient |
US5645829A (en) | 1993-06-18 | 1997-07-08 | Beth Israel Hospital Association | Mesothelial cell gene therapy |
AU710504B2 (en) | 1994-03-15 | 1999-09-23 | Brown University Research Foundation | Polymeric gene delivery system |
CA2185324A1 (en) * | 1994-03-16 | 1995-09-21 | Steven D. Rosen | Treating inflammation via the administration of specific sulfatase enzymes and/or sulfation inhibitor |
US5863782A (en) * | 1995-04-19 | 1999-01-26 | Women's And Children's Hospital | Synthetic mammalian sulphamidase and genetic sequences encoding same |
US5643599A (en) | 1995-06-07 | 1997-07-01 | President And Fellows Of Harvard College | Intracellular delivery of macromolecules |
US5736152A (en) | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
US7368531B2 (en) * | 1997-03-07 | 2008-05-06 | Human Genome Sciences, Inc. | Human secreted proteins |
US7083793B2 (en) * | 1999-02-26 | 2006-08-01 | Millennium Pharmaceuticals, Inc. | Tango 243 polypeptides and uses thereof |
AU3382800A (en) * | 1999-02-26 | 2000-09-14 | Millennium Pharmaceuticals, Inc. | Secreted proteins and uses thereof |
JP2002017376A (en) * | 1999-07-08 | 2002-01-22 | Herikkusu Kenkyusho:Kk | Secretory protein or membrane protein |
AU7099200A (en) * | 1999-09-03 | 2001-04-10 | Human Genome Sciences, Inc. | 52 human secreted proteins |
US6780627B1 (en) | 2000-01-31 | 2004-08-24 | Millennium Pharmaceuticals, Inc. | 22438, 23553, 25278, and 26212 novel human sulfatases |
CA2400034A1 (en) * | 2000-02-17 | 2001-08-23 | Incyte Genomics, Inc. | Human kinases |
EP1268541A1 (en) * | 2000-03-17 | 2003-01-02 | Human Genome Sciences, Inc. | 7 human ovarian and ovarian cancer associated proteins |
AU2001266557A1 (en) * | 2000-04-12 | 2001-10-23 | Human Genome Sciences, Inc. | Albumin fusion proteins |
AU2002211365A1 (en) | 2000-12-21 | 2002-07-08 | Millennium Pharmaceuticals, Inc. | 22437, a human sulfatase and uses therefor |
US20030148920A1 (en) * | 2000-12-27 | 2003-08-07 | Steven Rosen | Sulfatases and methods of use thereof |
US20030147875A1 (en) | 2000-12-27 | 2003-08-07 | Steven Rosen | Sulfatases and methods of use thereof |
WO2002098455A2 (en) * | 2001-06-07 | 2002-12-12 | Hemebiotech A/S | Production of recombinant human arylsulfatase a |
AU2002332648A1 (en) | 2001-08-31 | 2003-03-18 | Millennium Pharmaceuticals, Inc. | Mid 9002, a human sulfatase family member and uses therefor |
MX345056B (en) * | 2003-02-11 | 2017-01-16 | Transkaryotic Therapies Inc | Diagnosis and treatment of multiple sulfatase deficiency and other using a formylglycine generating enzyme (fge). |
US8510225B2 (en) | 2004-09-01 | 2013-08-13 | Research In Motion Limited | Split channel authenticity queries in multi-party dialog |
CN105450838B (en) | 2014-09-01 | 2019-12-24 | 联想(北京)有限公司 | Information processing method and electronic equipment |
-
2004
- 2004-02-10 MX MX2014003572A patent/MX345056B/en unknown
- 2004-02-10 JP JP2006503413A patent/JP5241101B2/en not_active Expired - Lifetime
- 2004-02-10 AT AT04709824T patent/ATE534730T1/en active
- 2004-02-10 EP EP10182644.4A patent/EP2325302B1/en not_active Expired - Lifetime
- 2004-02-10 EP EP04709824A patent/EP1592786B8/en not_active Expired - Lifetime
- 2004-02-10 US US10/775,678 patent/US8227212B2/en active Active
- 2004-02-10 SI SI200432307A patent/SI2325302T1/en unknown
- 2004-02-10 EP EP10182740.0A patent/EP2325301B1/en not_active Expired - Lifetime
- 2004-02-10 WO PCT/US2004/003632 patent/WO2004072275A2/en active Application Filing
- 2004-02-10 CA CA002515708A patent/CA2515708A1/en not_active Abandoned
- 2004-02-10 ES ES10182740.0T patent/ES2555056T3/en not_active Expired - Lifetime
- 2004-02-10 CN CN2004800064900A patent/CN1759176B/en not_active Expired - Lifetime
- 2004-02-10 NZ NZ603330A patent/NZ603330A/en not_active IP Right Cessation
- 2004-02-10 NZ NZ596420A patent/NZ596420A/en not_active IP Right Cessation
- 2004-02-10 ES ES10182644.4T patent/ES2566641T3/en not_active Expired - Lifetime
- 2004-02-10 AU AU2004210936A patent/AU2004210936C1/en not_active Expired
- 2004-02-10 DK DK04709824.9T patent/DK1592786T3/en active
- 2004-02-10 NZ NZ542267A patent/NZ542267A/en not_active IP Right Cessation
- 2004-02-10 CN CN2008102130733A patent/CN101444621B/en not_active Expired - Lifetime
- 2004-02-10 MX MXPA05008533A patent/MXPA05008533A/en active IP Right Grant
- 2004-02-10 CN CN201910517058.6A patent/CN110496230A/en active Pending
- 2004-02-10 PT PT04709824T patent/PT1592786E/en unknown
- 2004-02-10 CN CN201210302070.3A patent/CN103055306B/en not_active Expired - Lifetime
- 2004-02-10 HU HUE10182644A patent/HUE027210T2/en unknown
- 2004-02-10 DK DK10182644.4T patent/DK2325302T3/en active
- 2004-02-10 NZ NZ570201A patent/NZ570201A/en not_active IP Right Cessation
- 2004-02-10 ES ES04709824T patent/ES2380147T3/en not_active Expired - Lifetime
-
2005
- 2005-08-10 ZA ZA200506378A patent/ZA200506378B/en unknown
-
2006
- 2006-09-28 HK HK06110799.6A patent/HK1090088A1/en not_active IP Right Cessation
-
2010
- 2010-08-10 AU AU2010212261A patent/AU2010212261C1/en not_active Expired
-
2011
- 2011-06-16 HK HK11106228.8A patent/HK1152337A1/en not_active IP Right Cessation
- 2011-06-16 HK HK11106227.9A patent/HK1152336A1/en not_active IP Right Cessation
- 2011-10-27 JP JP2011235922A patent/JP5527854B2/en not_active Expired - Lifetime
-
2012
- 2012-02-27 US US13/406,154 patent/US20130172403A1/en not_active Abandoned
- 2012-06-20 US US13/528,657 patent/US20130028881A1/en not_active Abandoned
-
2014
- 2014-02-27 JP JP2014036642A patent/JP6007203B2/en not_active Expired - Lifetime
-
2016
- 2016-02-03 US US15/014,346 patent/US20160367703A1/en not_active Abandoned
- 2016-04-05 CY CY20161100271T patent/CY1117346T1/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE534730T1 (en) | DIAGNOSIS AND TREATMENT OF MULTIPLE SULFATASE DISEASES AND OTHERS USING AN ENZYME THAT PRODUCES FORMYLGLYCIN | |
EA200900802A1 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF AMYLOID DISEASES | |
IS7925A (en) | Hydroxyethylamine derivatives for the treatment of Alzheimer's disease | |
NO20055894L (en) | Methods and compositions for the treatment of amyloid-related diseases | |
NO20075693L (en) | Modulating compounds of indolamine-2,3-dioxygenase and methods for using the same | |
EA200602191A1 (en) | 5.5-DESIGNED-2-AMINO-4-THIAZOLIDINONES AND METHOD FOR THEIR PRODUCTION, PHARMACEUTICAL COMPOSITION AND METHOD OF TREATMENT | |
NO20071240L (en) | Therapeutic applications of RTP801 inhibitors | |
DK1620082T3 (en) | Medical use of inhibitors of glutaminyl and glutamate cyclases for the treatment of Alzheimer's disease and Down syndrome | |
NO20053114L (en) | Asthma and allergic inflammatory modulators. | |
DE602005017895D1 (en) | PYRAZOLAMIDE DERIVATIVES, COMPOSITIONS AND METHODS OF APPLYING THESE COMPOUNDS | |
DE602004020072D1 (en) | 1,2,3,4-TETRASUBSTITUTED INDOL FOR THE TREATMENT OF RESPIRATORY DISEASES | |
NO20055832L (en) | Preparation and use of arylalkyl acid derivatives for the treatment of obesity | |
IS8521A (en) | Tricyclic indole hydroxyethylamine derivatives and their use in the treatment of Alzheimer's disease | |
ATE453653T1 (en) | PLATINUM COMPLEXES FOR THE TREATMENT OF TUMORS | |
NO20064325L (en) | Heteroberlaminopyrazole derivatives useful for the treatment of diabetes | |
MA27880A1 (en) | TETRAHYDROCARBAZOLE DERIVATIVES AND THEIR PHARMACEUTICAL USE | |
ATE536859T1 (en) | MACA EXTRACT AND COSMETIC COMPOSITION CONTAINING THIS EXTRACT | |
HUP0302384A2 (en) | Compositions of biochemical compounds involved in bioenergy metabolism of cells and method of use | |
DE60112766D1 (en) | USE OF DERIVATIVES OF VALPROIC ACID AMIDE AND 2-VALPROIC ACID AMID FOR THE TREATMENT AND PREVENTION OF PAIN AND / OR HEADACHE | |
NO20075815L (en) | Formulations and methods for treating amyloidosis | |
MXPA05004621A (en) | Anilinopyrazole derivatives useful for the treatment of diabetes. | |
NO20054346L (en) | Compositions and methods for the prevention and treatment of endotoxin-related diseases and conditions | |
ATE519740T1 (en) | TETRAHYDROINDOLE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | |
DK1656360T3 (en) | Thiazoline derivatives as selective androgen receptor modulators | |
ATE482217T1 (en) | DITHIOLOPYRROLONE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISORDERS |